Cappella Medical Devices has announced the initial long term follow up data for its Sideguard coronary sidebranch stent from Manchester Royal Infirmary in the UK.

The stent was successfully implanted in 38 patients and showed no signs of peri-procedural complications, with MACE rates of 5.3% at the one-year follow-up.

The self-expanding nitinol stent features a proprietary split-sheath, balloon-released technology that ensures precise placement on the ostial borderline.

The Sideguard was developed to protect the ostium of the sidebranch in the treatment of bifurcation disease.

Previous results from the single centre clinical experience confirmed that preservation of the sidebranch of diseased coronary arteries by protecting the ostium has short and long-term benefits.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.